Hematopoietic toxicity produced by most anticancer drugs limits their potential for curative therapy. We have shown previously that the human cytidine deaminase ( CD ) gene can confer drug resistance in murine bone marrow cells ( BMCs ) to the nucleoside analog, cytosine arabinoside ( ARA -C ) . In the present study, as the first objective we showed that the CD gene can also render drug resistance in BMCs to related analogs, 2 0 ,2 0 -difluorodeoxycytidine ( dFdC ) and 5 -azadeoxycytidine ( 5 -AZA -CdR ) . As a second objective, we investigated the potential of ex vivo selection with cytosine nucleoside analogs of CD -transduced BMC. The goal of this approach was to enrich the fraction of CD -transduced BMCs so as to increase the transgene expression and level of drug resistance before transplantation. This strategy may have the potential to circumvent the problem in clinical gene therapy of low level of gene transfer and adequate long -term gene expression. Using a bicistronic retroviral vector containing the CD and the green fluorescent protein ( CDiGFP ) , we transduced murine L1210 leukemic cells. All three analogs, ARA -C, dFdC, and 5 -AZA -CdR were demonstrated in vitro to enrich ( > 95% ) the population of leukemic cells expressing the GFP transgene. However, with CD -transduced primary murine BMCs cultivated at high cell density we observed that in vitro selection with ARA -C was not possible due to release of CD into the culture medium at amounts that were sufficient to inactivate the analog. The CD -containing medium produced a chemoprotective effect on mock BMCs as shown by lack of significant growth inhibition in the presence of ARA -C. However, at low cell density in a cell mixture containing CD -transduced cells, the mock BMCs showed marked drug sensitivity to ARA -C as determined by clonogenic assay. Selection with ARA -C was shown to significantly increase the CD enzyme activity in transduced BMC. These results suggest that CD gene has the potential to be a good selectable marker and a possible tool for chemoprotection in cancer gene therapy. Cancer Gene Therapy ( 2001 ) 8, 669 -676
H ematopoietic stem cells are excellent targets for delivery of both therapeutic genes for genetic diseases and drug -resistance genes for chemoprotection in cancer therapy. However, the efficiency of gene transfer and longterm expression in vivo in human hematopoietic stem cells using retroviral vectors is usually very low. 1 -3 One reason for the low gene transfer efficiency of currently used retroviral vectors in human hematopoietic stem cells is that most of the cells are quiescent, rendering them resistant to transduction. 4 Consequently, it is likely that the therapeutic effect would be reduced and possibly inefficient. Low gene transfer and expression levels limit the potential of gene therapy for effective treatment of diseases. A very interesting approach to compensate for this limitation would be dominant selection ex vivo or in vivo of the gene -modified cells. 5 Several drug -resistance genes related to cancer have been investigated for their potential for protection of normal cells against cancer chemotherapy. The protection of normal cells from drug toxicity is an interesting approach to improve the effectiveness of cancer chemotherapy. Genes such as the multidrug resistance ( MDR ), the dihydrofolate reductase ( DHFR ), and methylguanine -DNA methyltransferase ( MGMT ) showed interesting activity in vitro and in vivo to protect cells from the toxic effects of MDR drugs, antifolates and alkylating agents, respectively. 5 -9 The MDR gene is already in clinical trial for chemoprotection. 10, 11 These drug -resistance genes have shown some variable potential to be used as selectable markers. 12 -16 We and others have reported that the human cytidine deaminase ( CD ) gene can confer drug resistance to cytosine arabinoside (ARA -C ), a deoxynucleoside analog used in cancer therapy. 17, 18 CD deaminates cytosine nucleoside analogs into inactive metabolites. 19, 20 These analogs are good candidates for chemoprotection and selection because they are S -phase specific and not toxic drugs for nondividing resting cells. Our objective was to investigate if cytosine nucleoside analogs can be useful tools for dominant selection of cells that express the drug -resistance transgene, CD. In this report we demonstrated that murine bone marrow cells ( BMCs ) transduced with a bicistronic retroviral vector containing the CD and the green fluorescent protein (GFP ) conferred drug resistance to two interesting deoxycytidine analogs, 2 0 ,2 0 -difluorodeoxycytidine (dFdC ) and 5 -azadeoxycytidine (5 -AZA -CdR ). Both these analogs show interesting potential in tumor therapy in patients. 21 -25 dFdC, 5 -AZA -CdR, and ARA -C were very efficient in vitro to select CD -transduced murine leukemic cells. However, we observed that in vitro selection of CD -transduced primary murine BMCs at high cell density was not possible due to the release of CD into the culture medium at amounts that were sufficient to inactivate the analog.
MATERIALS AND METHODS

Vector construct and packaging cells
The pMSCV-iGFP expression vector (kindly donated by Dr. Jacques Galipeau, Lady Davis Institute, Montreal, Canada ) was used for the construction of the pMSCV-CDiGFP vector. Briefly, the CD cDNA was first removed from the pMFG -CD plasmid by sequential NcoI and BamHI enzymatic digestion to create the NcoI blunt end. The pMSCV-iGFP plasmid was also sequentially digested at XhoI and BamHI sites to make the XhoI blunt end and ligated to the previously hemiblunted CD fragment. The proper DNA sequence of the CDiGFP cassette was confirmed by measuring the activity of the two proteins in cells. This vector was first transfected into GP +envAM12 amphotropic packaging cell line and virions collected from that cell line were used to transduced the ecotropic GP +E86 packaging cell line (Dr. A. Bank, Columbia University, New York, NY ). The titer of the retroviral GP + E86 CDiGFP packaging cell line was 1Â10 6 infectious particles /mL. The vector integrity after genomic incorporation was verified by Southern blot analysis ( data not shown ).
L1210 cell culture and transduction
Leukemic L1210 murine cells were grown in RPMI1640 medium ( Gibco, Burlington, Ontario) supplemented with 5% FBS and 55 M mercaptoethanol under an atmosphere of 5% C0 2 at 378C. Cells were transduced by cocultivation with the GP + E86 CDiGFP retroviral packaging cell line. Briefly, 1Â10 5 L1210 cells were seeded over irradiated producers (20 Gy ) for 24-48-hour periods in L1210 growth medium in the presence of 6 g /mL polybrene. Transduction efficacy was monitored by flow cytometry.
Murine bone marrow transduction and growth culture conditions
BMCs were collected from 8 -to 15 -week -old Balb / C male mice ( Charles River Canada, St -Constant, Quebec, Canada ) 4 days after treatment with 150 mg /kg 5-fluorouracil.
The cells were then cocultivated for 72 hours with subconfluent irradiated ( 20 Gy ) GP +E86 CDiGFP producer cells. The viral titer of the producer cells was sufficient to transduce 60 -80% of target cells as determined by flow cytometry. For mock transduction parental GP + E86 packaging cells were used. The cocultivation medium contained 10 mg /mL bovine serum albumin, 0.3 mg /mL human transferrin ( Boehringer Mannheim, Laval, Quebec ), 6 g/ mL polybrene, 10% WEHI -3B and HTB -9 conditioned medium, 20% FBS in alpha -MEM, and 5 g/mL gentamycin ( Sigma, St. Louis, MO ) . BMCs were maintained in the same medium for growth assay except that polybrene was not added. Transduced BMCs were then collected, counted and plated at (1 -2 )Â10 6 cells/ mL of culture medium in a 5% CO 2 incubator at 378C for growth assays.
Colony -forming unit assay
After transduction, BMCs [ ( 1 -2 )Â10 6 cells /mL ] in suspension were preselected with ARA -C for 72 hours where indicated and then plated in 1% methylcellulose medium (Stem Cell Technologies, Vancouver, British Columbia ) at a density of (2 -3) Â10 4 cells/mL. After 7-9 days of growth, colony forming units ( CFU, > 50-100 cells) were counted.
FACS analysis and GFP detection
Murine leukemic L1210 or primary BMCs were first washed with phosphate -buffered saline ( PBS ) solution and than incubated for 20 minutes with the Becton Dickinson FACS solution ( Becton Dickinson, Mississauga, Ontario, Canada ). After centrifugation, cells were once again washed in PBS solution and finally suspended in appropriate volume of 1% paraformaldehyde in PBS before analysis.
Cytidine deaminase enzyme assay
Cytosol aliquots were prepared as follows: ( 5 to 10 )Â10 6 primary BMCs were centrifuged and washed once in PBS. They were then centrifuged and resuspended in 100 L of 5 mM Tris -HCl, pH 7.4, and 5 mM dithiothreitol. Cell membranes were than lysed following three sets of freezing and thawing. The resulting mixture was centrifuged at 14,000 rpm for 15 minutes at 48C. The supernatant (cytosol ) molarity was then adjusted to 50 mM Tris -HCl, pH 7.4 and the protease inhibitors leupeptine, aprotinine, and pepstatine ( Boehringer Mannheim ) were added to a final concentration of 1 ng/L. CD activity was determined by measuring the conversion of 3 H cytidine to 3 H uridine with 5 L of cytosol or filtered culture supernatant following a 30-minute incubation at 378C. Protein concentration was determined using the Bio -Rad kit and bovine serum albumin as internal standard.
RESULTS
Chemoprotection of murine BMCs to dFdC and 5 -AZA -CdR
Previous work from our laboratory showed that the CD gene has the potential to confer in vitro chemoprotection against ARA -C in murine BMCs using the MFG retroviral vector. 17 In this study we transduced the BMCs using the MSCV retroviral vector containing the bicistronic CDiGFP cassette to determine if drug resistance could be conferred to dFdC and 5 -AZA -CdR, two other deoxycytidine analogs. CD gene -modified BMCs showed remarkable clonogenic drug resistance to dFdC with > 90% protection at a concentration that kills almost all the control mock infected cells ( Fig 1A ) . In a similar experiment using 5 -AZA -CdR, only a modest but significant increase in drug resistance was observed ( Fig  1B ) . Transduction efficacy was > 90% as drug resistance to dFdC in the CFU -C type assay was observed to be > 90%. FACS analyses were in accordance with such high gene transfer efficiency with 60-80% GFP positive cells after cocultivation (data not shown) . We speculate that the 20 -40% GFP negative cells were terminally differentiated or dead cells that were not transduced and could not give rise to colony formation in methylcellulose. Also, it is possible that some CD positive cells had undetectable GFP expression.
In vitro selection of CD -transduced L1210 leukemic cells with deoxycytidine analogs
To assess the potential of the CD gene as a selectable marker, we first investigated L1210 leukemic cells. These cells have similar in vitro sensitivity to deoxycytidine analogs as primary murine BMCs (data not shown ). Close to 100% CDiGFP -transduced L1210 cells were obtained by multiple rounds of infection. These cells were subsequently mixed with mock cells at a 1:4 ratio ( Fig 2C ) . These cell mixtures, after 72 hours exposure to either ARA -C, dFdC, or 5 -AZACdR, were allowed to grow for different periods of time before FACS analysis. This analysis revealed remarkable in vitro drug selection for all three analogs tested with values passing from 20% to > 95% CDiGFP positive cells (Fig  2D -F ) . The concentration used for the analogs was previously found to produce >90% growth inhibition for control L1210 cells. A similar experiment was performed with the adherent human A -549 lung carcinoma cells. Starting with a mixed population of 20% CDiGFPtransduced and 80% untransduced tumor cells, it was possible to increase up to >90% the GFP positive cells following 4 -day exposure to 0.1 M ARA -C (data not shown) .
In vitro selection of CD -transduced BMCs with ARA -C
Similar experiments were performed with murine BMCs using only ARA -C as selective agent. CDiGFP -transduced murine BMCs were mixed with mock -transduced murine BMCs to obtain a 1:4 ratio. Following 72 hours of ARA -C drug selection at 1 M, FACS analyses were performed and surprisingly no enrichment for the CDiGFP positive cells was observed ( Fig 3A ) . To ensure that the GFP signal was not only abrogated and that no selection occurred, CD enzyme activities were measured before and after drug selection on 20% CDiGFP BMCs and no increase in the CD activity was observed (Table 1 ) . These results were unexpected because mock -transduced cells were efficiently killed by the ARA -C concentration used in a cell growth assay. In fact, less than 10% of mock cells survived growth inhibition produced by 1 M ARA -C ( Fig 3B ) . The cell mixture at a 1:4 ratio ( 20% ) or even as low as a 1:20 ratio ( 5% ) of CDiGFP cells over mock cells showed the same level of drug resistance as only the CDiGFP cell population in this growth assay (Fig 3B ) .
We suspected that some sort of bystander effect was produced by CD -transduced cells on the mock neighboring cells. Actually, we observed that a protective effect was produced by the release into the culture medium of CD from the cytoplasm of the CD positive dying cells. This hypothesis was validated by the observation that filtered medium collected from CD -transduced BMCs was capable of protecting almost completely mock cells against 1 M ARA -C (Fig 3B ) . Recombinant virus containing the CD gene did not infect these mock cells because they recovered their drug sensitivity to ARA -C when washed free from the CD medium. In accord with these observations, CD enzyme activity was only detected in the supernatant of CDtransduced BMCs (Table 2 ). Our hypothesis is that this protective phenomenon was present only with primary murine BMC, not with L1210 cells, as only primary BMCs have high cell turnover and were cultured at high cell density. This was verified by the fact that the same 20% CDiGFP murine BMC population that was > 90% drug BEAUSÉJOUR, ET AL: CD GENE AS A SELECTABLE MARKER resistant in a growth assay was only about 20% drug resistant when placed in methylcellulose at low cell density for a CFU -C assay ( Fig 4) .
DISCUSSION
Most gene therapy strategies for both cancer and genetic diseases are currently limited by suboptimal gene transfer procedures into long -term repopulating stem cells. Hematopoietic stem cells are good candidates for prolonged expression of the transgene as they are easily accessible, and can be purified and manipulated ex vivo before being safely transplanted back into the host. Retroviral vectors used currently to obtain stable integration of the transgene are inefficient to achieve high -level gene transfer in quiescent stem cells and sustain high -level expression of the transgene. Efforts at improving gene transfer into hematopoietic stem cells are numerous and include varying the pseudotype of the viral envelope protein. 26 Other investigators have tried to stimulate stem cell replication by the addition of different cytokine combinations, even though this strategy may result in diminished long -term repopulating ability of progenitors cells. 27 -29 The development of the newly base lentiviral vectors is one solution to increase gene transfer into quiescent nondividing hematopoietic stem cells. 30 However, concerns about their safety may delay their utilization in clinical trials. An interesting approach to surmount these limitations would be to ex vivo or in vivo select modified cells. In one of the first reports of effective gene therapy in humans, the authors note that the success obtained could be attributed to the natural selection property conferred to their transduced cells. 31 Several drug -resistance genes have been evaluated for their potential to act as selectable markers in vivo. Among them, the MDR gene was the first one to be tested for this activity. 12, 13 The ability of MDR gene to act as a selectable marker and confer chemoresistance is convincing in animal model, but as yet to be proven in human studies. In clinical trials, inappropriate gene transfers into truly long -term repopulating stem cells as well as suboptimal drug pressure BEAUSÉJOUR, ET AL: CD GENE AS A SELECTABLE MARKER were cited as one of the major limitations. 10, 11 Rapid appearance of drug resistance to MDR-related drugs in nonmodified stem cells might limit the selective potential of this gene. In addition, MDR -transduced BMCs were reported to cause a myeloproliferative syndrome in transplanted mice. 32 The DHFR gene is also a promising candidate for conferring chemoprotection and in vivo selection. It was reported that mice transplanted with DHFR -transduced BMCs had evidence of improved curability and reduced drug toxicities to methotrexate (MTX ), an antifolate drug. 8 Trimetrexate and a nucleoside transport inhibitor ( to prevent thymidine rescue ) also showed promising results for in vivo selection in DHFR transplanted mice. 15 However, only modest results were obtained more recently in mice using methotrexate alone as the selective agent. 16 In this latter study, selection was not possible in non-ablated animals indicating that selection is dependent on the ratio of transduced / nontransduced hematopoietic stem cells. The omission of the nucleoside transporter inhibitor greatly compromise the MTX toxicity in nontransduced stem cells that may have escaped drug pressure by using extracellular thymidine as a salvage pathway. Also, Blau and coworkers 33 reported that MTX was inefficient at killing cells at the progenitor level. 33 Finally, the MGMT gene is certainly considered as one of the most promising in vivo selectable markers. The mutated form of the gene, in combination with O 6 -benzylguanine and BCNU, did confer chemoresistance and delayed tumor progression in mice. 6 Furthermore, this combination was shown to be very effective to in vivo select myeloablated and nonmyeloablated mice repopulate with only low number of modified cells.
14 Thus far, no in vivo data on humans has been reported, but a clinical trail was recently approved. 14 However, alkylating agents are very toxic drugs and their use in clinical trials on gene therapy of disease may not be approved due to their severe side effects because these agents would have to be used on a routine basis.
Another interesting strategy to induce in vivo selection of gene -modified cells has been reported recently. 34 The approach is based on the induction of growth by the activation of a signaling domain of a growth factor receptor by a chemical inducer. This illustrates the current interest for the development of new selection techniques.
The ideal drug -resistance gene should ( i) confer high levels of drug resistance to possibly more then a single drug, ( ii ) be non immunogenic, (iii ) be of small size to facilitate its linkage to a therapeutic gene, and (iv ) confer resistance to a class of drugs that are not too toxic, not mutagenic or carcinogenic, allowing continued in vivo administration after transplantation. Cytosine nucleoside analogs are effective anticancer drugs. We have demonstrated that elevated activity of the CD gene is one mechanism responsible for the resistance observed against these analogs. 35 We feel that the human CD drug -resistance gene fulfills most of these criteria to be considered as an effective drug selectable marker.
In this study, we evaluated the potential of the CD gene to act as a drug -resistance gene and a selectable marker. CD overexpression in murine BMCs is known to confer ARA -C resistance. 17, 36 One objective was to determine if this resistance occurs with other deoxycytidine analogs. High level of drug resistance was found against dFdC with lower, but significant, resistance against 5 -AZA -CdR ( Fig 1) . These findings are promising for future studies on chemoprotection because dFdC and 5-AZA -CdR are active drugs Where indicated the cells were selected in the indicated concentrations of ARA -C for 72 hours. CD activity in cytosol of the cells was determined as described in Materials and methods. Mean values ± SD for three to four determinations are shown. The cells were grown in culture medium for 72 hours. The medium was then passed through a 0.2 -m filter and 5 L was added to the reaction mixture of the CD assay. Mean values ± SD for three to four determinations are shown. ND, not detectable. against solid tumors, whereas ARA -C is mainly used for acute leukemia. In comparison with the in vitro antineoplastic activity of these two analogs, 5 -AZA -CdR shows less activity due to its chemical instability because it has a half -life of only about 12 hours in culture medium.
Our next objective was to demonstrate that CD with a deoxycytidine analog can be used as a potent drug selectable gene. In in vitro studies using L1210 leukemic cells, CD showed a remarkable capacity to act as a selectable marker ( Fig 2) . Starting from a population containing only 20% CD -modified cells, all three analogs tested were able to enrich ( >95% ) for drug -resistant cells. Comparable results were observed with a starting population of only 5% to 10% CD positive cells (data not shown) . CD in vitro selection potential with ARA -C was also observed to function very well with adherent human A -549 lung carcinoma cells.
Similar experiments were performed on murine BMCs. CD -transduced primary murine BMCs cultivated at high cell density showed that in vitro selection with ARA -C was not possible due to release of CD into the culture medium in sufficient amounts to inactivate the analog at a concentration known to normally produce > 90% growth inhibition ( Fig  3B and Table 2 ) . One explanation for this phenomenon is that primary BMCs cultured at high cell density have a rapid turnover. This event was not seen when primary BMCs were cultivated at low cell density in methylcellulose (Fig 4) . We cannot rule out the possibility that BMCs negative for the GFP signal, but positive for CD, were selected. However, this possibility is improbable because CD enzyme activity was not increased after ARA -C selection on the 20% CDiGFP BMCs starting population (Table 1 ) . However, we think that these results will not compromise the potential of the CD gene to act as a selectable marker in vivo, because rapid clearance of the CD protein from the marrow would take place. The pharmacokinetic parameters of cytosine nucleoside analogs should be taken into account for their use for in vivo selection. Low -dose chemotherapy would not be suitable to obtain these objectives because the concentrations of the analogs in the body fluids will be in the range of the minimal cytotoxic concentration. In those tissues that have significant CD activity, the drug level can even fall below the minimal cytotoxic concentration that is unsuitable for selection. For these reasons we favor an intermediate dose schedule that produces levels in the body fluids considerably above the minimal cytotoxic concentration.
ARA -C ex vivo selection of CDiGFP-transduced BMCs did not lead to a significant increase in CFU -C survival ( data not shown ) . However, we observed a significant increase, more than 2 -fold, of the transgene expression in those cells following selection with ARA -C at high concentrations ( Table 1 ). These findings suggest that ex vivo selection of BMCs expressing high level of CD protein may be possible at an elevated ARA -C concentration. Ex vivo selection of BMCs with MDR drugs also produced elevated transgene expression and showed increase chemoresistance in reconstituted bone marrow of mice. 37, 38 We can conclude that the human CD gene is able to chemoprotect murine BMCs against diverse deoxycytidine analogs. This protection is high enough to allow excellent in vitro selection potential. These results should be seen as good basis on which future in vivo experiments will be designed.
In conclusion, we propose that the human CD has the potential to be an effective selectable gene under in vitro conditions using different cytosine nucleoside analogs. We feel that the combination of CD and these analogs should be considered as a promising selection strategy. One limitation of our system is poor selection efficacy on nondividing stem cells. We believe that this may be overcome by appropriate sequential drug pressure and /or cytokine prestimulation in vivo. 39 Future improvements in methods of gene transfer and expression may lead to the effective use of CD in an in vivo setting for both selection and chemoprotection.
